NLRP3 and Alzheimer disease: Drugs such as Dihydromyricetin [259] or MCC950 [260] blocking NLRP3 inflammasome signaling promoted the clearance of Aβ, decreased the fraction of M1 activated microglia in the hippocampus and cerebral cortex, and ameliorated memory and cognitive deficits in APP/PS1 AD-model mice.